WEBSITE BSE:0 NSE: Inc. Year: 2010 Industry: Animal Feed My Bucket: Add Stock
Last updated: 15:45
No Notes Added Yet
1. Business Overview
Ajooni Biotech Ltd. is an Indian company primarily engaged in the manufacturing and selling of various types of animal feed. Its core business model involves producing compound feed products, such as cattle feed, poultry feed, and potentially feed for other livestock or aquaculture, using a mix of agricultural raw materials and supplements. The company generates revenue by selling these feed products directly to farmers, dairy owners, poultry farms, and through a network of distributors. The aim is to provide nutritious and balanced feed to improve animal health, productivity, and yield for its customers.
2. Key Segments / Revenue Mix
The company's primary revenue stream is derived from the sale of animal feed products. While specific sub-segment contributions are not publicly available, it likely includes:
Cattle Feed: For dairy and beef cattle.
Poultry Feed: For broiler and layer chickens.
Given its industry focus, a vast majority, if not all, of its revenue comes from the animal feed segment.
3. Industry & Positioning
The Indian animal feed industry is characterized by a mix of organized national players and numerous regional and local manufacturers. It is a growing sector driven by increasing demand for animal protein, professionalization of livestock farming, and a shift towards compound feed. Ajooni Biotech Ltd. likely operates as a regional player, competing with both larger established companies that have national distribution networks and other local manufacturers. Its positioning would depend on its geographical presence, product specialization, and pricing strategy within specific states or districts in India.
4. Competitive Advantage (Moat)
Ajooni Biotech Ltd. is likely to have a limited competitive moat.
Brand: It may have established some regional brand recognition and loyalty among local farmers, but it is unlikely to possess a strong national brand moat against larger players.
Scale: While it might achieve some economies of scale within its operating regions, it likely doesn't have a significant scale advantage over large national competitors.
Distribution Network: A well-established local/regional distribution network and strong relationships with farmers and distributors could provide a minor advantage.
Switching Costs: Switching costs for farmers are generally low, as many feed products are interchangeable unless specific formulations offer demonstrably superior results.
Overall, competitive advantages are likely to be moderate, relying on product quality, pricing, and localized customer service.
5. Growth Drivers
Rising Demand for Animal Protein: India's growing population and increasing disposable incomes are fueling higher consumption of milk, eggs, and meat, consequently driving demand for animal feed.
Professionalization of Farming: A shift from traditional subsistence farming to commercial dairy, poultry, and aquaculture operations increases the demand for scientifically formulated, high-quality compound feed.
Government Support: Initiatives to boost the livestock and dairy sectors often provide a conducive environment for feed manufacturers.
Product & Geographical Expansion: Expanding the product portfolio to include new feed types (e.g., aquaculture feed) or increasing geographical reach can drive growth.
Improved Feed Efficiency: Farmers' increasing awareness about the economic benefits of better feed for higher yields and animal health.
6. Risks
Raw Material Price Volatility: Key inputs such as grains (maize, soy), oilseed meals, and other supplements are agricultural commodities subject to price fluctuations due to weather, government policies, and global supply-demand dynamics.
Intense Competition: The industry is highly competitive, leading to pricing pressures and potential erosion of margins from both large organized players and local unorganized manufacturers.
Disease Outbreaks: Outbreaks of animal diseases (e.g., bird flu, African Swine Fever) can severely impact livestock populations and, consequently, the demand for feed.
Regulatory Changes: Changes in regulations regarding feed quality, ingredients, or environmental norms can impact production costs and processes.
Weather Dependence: Adverse weather conditions can affect crop yields, impacting raw material availability and prices.
Credit Risk: Dependence on timely payments from farmers and distributors, especially in agricultural cycles.
7. Management & Ownership
Ajooni Biotech Ltd. is typically promoted and managed by its founding family, a common structure for many small and mid-sized companies in India. The vision, experience, and leadership quality of the promoters play a crucial role in the company's strategic direction and execution. Ownership is likely promoter-dominated, with public shareholders holding the remainder. The management team would typically include a mix of family members and professional managers overseeing operations, sales, and finance.
8. Outlook
Ajooni Biotech operates in a fundamentally growing sector driven by India's demographic and economic trends, particularly the increasing demand for animal protein. This provides a tailwind for the company's core business. The professionalization of farming practices also supports a shift towards organized compound feed. However, the business faces significant challenges including intense price competition, volatility in raw material costs, and the inherent risks associated with livestock farming such as disease outbreaks. The ability of Ajooni Biotech to manage raw material sourcing efficiently, expand its distribution network, maintain product quality, and potentially diversify its product offerings will be critical for sustained growth and profitability in a competitive and cyclical industry.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹72 Cr.
Stock P/E 21.3
P/B 0.8
Current Price ₹4.2
Book Value ₹ 5.3
Face Value 2
52W High ₹6.6
Dividend Yield 0%
52W Low ₹ 3.6
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 19 | 20 | 20 | 26 | 26 | 34 | 29 | 31 | 32 | 59 |
| Other Income | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Total Income | 20 | 22 | 20 | 26 | 26 | 34 | 31 | 32 | 32 | 59 |
| Total Expenditure | 19 | 21 | 18 | 25 | 25 | 33 | 28 | 31 | 30 | 56 |
| Operating Profit | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 |
| Provision for Tax | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit After Tax | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 2 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 2 |
| Adjusted Earnings Per Share | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0.1 | 0 | 0.1 | 0.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 7 | 13 | 29 | 42 | 40 | 40 | 51 | 74 | 74 | 80 | 115 | 151 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Total Income | 7 | 13 | 29 | 43 | 40 | 40 | 51 | 74 | 75 | 82 | 117 | 154 |
| Total Expenditure | 7 | 13 | 28 | 41 | 39 | 39 | 49 | 71 | 72 | 78 | 111 | 145 |
| Operating Profit | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 6 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 | 6 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 6 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 6 |
| Adjusted Earnings Per Share | 0.2 | 0.3 | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 44% | 16% | 24% | 32% |
| Operating Profit CAGR | 50% | 26% | 43% | 0% |
| PAT CAGR | 50% | 44% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -29% | -2% | -13% | NA% |
| ROE Average | 5% | 5% | 5% | 10% |
| ROCE Average | 7% | 7% | 7% | 12% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 0 | 1 | 1 | 11 | 12 | 16 | 16 | 16 | 42 | 43 | 88 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 1 | 0 | 4 | 1 | 2 | 3 | 2 | 2 | 2 |
| Other Non-Current Liabilities | 0 | -0 | 3 | 2 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Total Current Liabilities | 1 | 2 | 8 | 6 | 2 | 6 | 10 | 10 | 15 | 3 | 5 |
| Total Liabilities | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 58 | 47 | 95 |
| Fixed Assets | 0 | 0 | 1 | 1 | 1 | 2 | 4 | 6 | 6 | 10 | 11 |
| Other Non-Current Assets | 0 | 0 | 6 | 7 | 5 | 3 | 3 | 1 | 17 | 5 | 21 |
| Total Current Assets | 1 | 2 | 6 | 11 | 12 | 18 | 21 | 22 | 35 | 32 | 62 |
| Total Assets | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 58 | 47 | 95 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | -1 | 0 | 0 | -5 | -4 | 1 | 4 | -6 | 23 | -18 |
| Cash Flow from Investing Activities | -0 | -0 | 0 | 0 | 1 | 0 | -3 | -2 | -16 | 8 | -17 |
| Cash Flow from Financing Activities | 0 | 1 | 0 | 0 | -1 | 3 | 2 | -2 | 22 | -4 | 25 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 0 | -5 | -1 | 0 | -0 | 0 | 27 | -10 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 27 | -10 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.2 | 0.27 | 0.55 | 0.12 | 0.12 | 0.07 | 0.07 | 0.21 | 0.13 | 0.25 | 0.2 |
| CEPS(Rs) | 0.29 | 0.47 | 0.93 | 0.22 | 0.25 | 0.18 | 0.19 | 0.4 | 0.24 | 0.35 | 0.26 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 1.18 | 1.45 | 1.92 | 3.19 | 3.43 | 3.34 | 3.1 | 3.27 | 4.76 | 4.87 | 5.09 |
| Core EBITDA Margin(%) | 1.83 | 1.74 | 2.34 | 2.19 | 1.78 | 3.02 | 3.23 | 3.96 | 3.71 | 2.79 | 3.22 |
| EBIT Margin(%) | 1.49 | 1.22 | 1.84 | 1.97 | 1.53 | 2.02 | 2.13 | 2.7 | 2.76 | 4.43 | 4.07 |
| Pre Tax Margin(%) | 1.46 | 1.07 | 1.36 | 1.15 | 1.2 | 1.2 | 0.99 | 1.97 | 2.12 | 3.74 | 3.77 |
| PAT Margin (%) | 1.01 | 0.73 | 0.97 | 0.91 | 1.03 | 0.87 | 0.73 | 1.42 | 1.51 | 2.7 | 2.94 |
| Cash Profit Margin (%) | 1.45 | 1.27 | 1.64 | 1.65 | 2.14 | 2.1 | 1.86 | 2.73 | 2.86 | 3.79 | 3.89 |
| ROA(%) | 6.89 | 4.78 | 3.61 | 2.4 | 2.2 | 1.69 | 1.47 | 3.7 | 2.58 | 4.09 | 4.75 |
| ROE(%) | 18.72 | 20.38 | 36.98 | 6.8 | 3.72 | 2.54 | 2.4 | 6.58 | 3.87 | 5.12 | 5.18 |
| ROCE(%) | 27.57 | 18.62 | 36.19 | 10.03 | 3.84 | 4.35 | 5.07 | 9.09 | 5.99 | 7.75 | 6.94 |
| Receivable days | 22.49 | 27.7 | 16.1 | 17.94 | 35.36 | 79.67 | 94.23 | 67.91 | 84.26 | 76.34 | 46.43 |
| Inventory Days | 13.4 | 10.6 | 29.6 | 26.78 | 32.48 | 38.09 | 30.97 | 27.75 | 31.55 | 50.94 | 62.62 |
| Payable days | 36.96 | 31.05 | 45.37 | 29.93 | 10.48 | 16.19 | 31.11 | 34.78 | 46.94 | 30.34 | 9.55 |
| PER(x) | 0 | 0 | 0 | 37.96 | 23.11 | 14.32 | 63.36 | 49.93 | 27.12 | 21.09 | 28.6 |
| Price/Book(x) | 0 | 0 | 0 | 1.41 | 0.81 | 0.32 | 1.52 | 3.2 | 0.73 | 1.07 | 1.1 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.01 | 0.07 | 0.03 | 0.43 | 0.41 | 0.28 | 0.72 | 0.98 | 0.53 | 0.67 | 0.8 |
| EV/Core EBITDA(x) | 0.75 | 4.07 | 1.19 | 15.86 | 15.57 | 8.68 | 22.19 | 24.44 | 12.9 | 12.07 | 15.91 |
| Net Sales Growth(%) | 1166.04 | 83.46 | 115.71 | 48.51 | -6.27 | 0.79 | 27.49 | 45.06 | 0.61 | 7.55 | 43.16 |
| EBIT Growth(%) | 785.95 | 50.37 | 224.98 | 59.38 | -27.43 | 33.45 | 34.59 | 83.88 | 2.69 | 72.89 | 31.26 |
| PAT Growth(%) | 845.45 | 32.55 | 185.79 | 40 | 6.45 | -15.62 | 7.57 | 181.14 | 7.24 | 92.16 | 56.02 |
| EPS Growth(%) | 845.45 | 32.55 | 103.17 | -78.26 | 1.26 | -38.2 | 0.44 | 180.97 | -38.74 | 92.13 | -20.63 |
| Debt/Equity(x) | 0 | 1.5 | 0.64 | 0.45 | 0.41 | 0.32 | 0.44 | 0.33 | 0.12 | 0.05 | 0.02 |
| Current Ratio(x) | 1.19 | 1.25 | 0.73 | 1.87 | 6.14 | 3 | 2.05 | 2.18 | 2.28 | 10.74 | 12.86 |
| Quick Ratio(x) | 0.89 | 1 | 0.22 | 1.56 | 3.54 | 2.43 | 1.53 | 1.6 | 1.82 | 5.63 | 7.89 |
| Interest Cover(x) | 63.06 | 7.94 | 3.84 | 2.41 | 4.63 | 2.47 | 1.86 | 3.71 | 4.3 | 6.38 | 13.95 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.25 | 0.39 | 0.79 | 0.22 | 0.08 | 0.15 | 0.04 | 0.02 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.44 | 26.44 | 26.89 | 26.89 | 26.89 | 26.89 | 26.89 | 26.89 | 26.89 | 26.89 |
| FII | 0 | 0 | 0 | 0.29 | 0.18 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 73.56 | 73.56 | 73.11 | 72.82 | 72.92 | 73.11 | 73.11 | 73.11 | 73.11 | 73.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.32 | 2.32 | 4.63 | 4.63 | 4.63 | 4.63 | 4.63 | 4.63 | 4.63 | 4.63 |
| FII | 0 | 0 | 0 | 0.05 | 0.03 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 6.45 | 6.45 | 12.59 | 12.54 | 12.56 | 12.59 | 12.59 | 12.59 | 12.59 | 12.59 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.76 | 8.76 | 17.22 | 17.22 | 17.22 | 17.22 | 17.22 | 17.22 | 17.22 | 17.22 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.